Chidamide

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Funders: National Natural Science Foundation of China and 3 more

Human trial1
Animals1

Outcomes

Pancreatic ductal adenocarcinoma

downin human cells1

1 study

Chidamide inhibits pancreatic ductal adenocarcinoma in human cells.
“selective clearance of senCAFs via chidamide, attenuated tumor progression”
Cellsselective clearance of senCAFs
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring
Cancer discovery27 Mar 2026

More on Pancreatic ductal adenocarcinoma

Microbiome composition

upin mice1

1 study

Chidamide improves microbiome composition in mice.
“TUC reshapes the gut microbiota-metabolite axis by promoting the proliferation of beneficial bacteria”
AnimalsDSS-induced ulcerative colitis
Tucidinostat ameliorates DSS-induced ulcerative colitis by inhibiting cellular senescence, modulating the p53 signaling pathway and cell cycle, and restoring the gut microbiota-metabolite Axis
International immunopharmacology3 Jan 2026

Latest

2 in 12 months

Cancer Discovery27 Mar

Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring

Non-randomised trial in peoplePancreatic cancer

Paper

International Immunopharmacology4 Jan

Tucidinostat ameliorates DSS-induced ulcerative colitis by inhibiting cellular senescence, modulating the p53 signaling pathway and cell cycle, and restoring the gut microbiota-metabolite Axis

Experiments in miceGut and microbiome